Skip to main content

Stem Cell Stocks Seek Comeback

Dont expect stem cell stocks to lag the rest of the biotech sector again in 2014, says Dr. Robin Smith, CEO of Neostem.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

TheStreet Recommends